我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
8
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2009
进行中（未招募）
3
37.5%
已完成
5
62.5%
暂无批准数据
- Journal of Critical Care has published positive results from AdrenoMed's Phase II AdrenOSS-2 trial, showing enibarcimab improved organ function and reduced 28-day mortality in septic shock patients. - The precision medicine approach used two biomarkers (bio-ADM and DPP3) to identify patients most likely to benefit from treatment, with mortality rates of 18% in the enibarcimab group versus 26% in placebo. - Based on these promising findings, AdrenoMed is advancing to a confirmatory Phase IIb/III BOOST trial, potentially addressing a critical unmet need in septic shock treatment where mortality rates remain at 30-50%.
